Cyclin D1 Antibody - #DF6386

(11)   (14)  
Product: Cyclin D1 Antibody
Catalog: DF6386
Description: Rabbit polyclonal antibody to Cyclin D1
Application: WB IHC IF/ICC
Cited expt.: WB, IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Dog, Chicken, Xenopus
Mol.Wt.: 34kDa; 34kD(Calculated).
Uniprot: P24385
RRID: AB_2838349

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(86%), Bovine(86%), Dog(86%), Chicken(86%), Xenopus(86%)
Clonality:
Polyclonal
Specificity:
Cyclin D1 Antibody detects endogenous levels of total Cyclin D1.
RRID:
AB_2838349
Cite Format: Affinity Biosciences Cat# DF6386, RRID:AB_2838349.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

AI327039;B cell CLL/lymphoma 1;B cell leukemia 1;B cell lymphoma 1 protein;B-cell lymphoma 1 protein;BCL 1;BCL-1;BCL-1 oncogene;BCL1;BCL1 oncogene;ccnd1;CCND1/FSTL3 fusion gene, included;CCND1/IGHG1 fusion gene, included;CCND1/IGLC1 fusion gene, included;CCND1/PTH fusion gene, included;CCND1_HUMAN;cD1;Cyl 1;D11S287E;G1/S specific cyclin D1;G1/S-specific cyclin-D1;Parathyroid adenomatosis 1;PRAD1;PRAD1 oncogene;U21B31;

Immunogens

Immunogen:

A synthesized peptide derived from human Cyclin D1, corresponding to a region within C-terminal amino acids.

Uniprot:

P24385(CCND1_HUMAN) >>Visit HPA database.

Gene(ID):
CCND1(595)
Description:
Activity of the cyclin-dependent kinases CDK4 and CDK6 is regulated by T-loop phosphorylation, by the abundance of their cyclin partners (the D-type cyclins), and by association with CDK inhibitors of the Cip/Kip or INK family of proteins (1). The inactive ternary complex of cyclin D/CDK4 and p27 Kip1 requires extracellular mitogenic stimuli for the release and degradation of p27 concomitant with a rise in cyclin D levels to affect progression through the restriction point and Rb-dependent entry into S-phase (2). The active complex of cyclin D/CDK4 targets the retinoblastoma protein for phosphorylation, allowing the release of E2F transcription factors that activate G1/S-phase gene expression (3). Levels of cyclin D protein drop upon withdrawal of growth factors through downregulation of protein expression and phosphorylation-dependent degradation (4). Of the three D cyclins, aberrant expression of cyclin D1 has been associated with many forms of cancer including B cell lymphomas and can directly contribute to oncogenesis by various mechanisms including gene translocation or amplification (2). Cyclin D1 also plays a critical role in mammary tissue maturation (5).
Sequence:
MEHQLLCCEVETIRRAYPDANLLNDRVLRAMLKAEETCAPSVSYFKCVQKEVLPSMRKIVATWMLEVCEEQKCEEEVFPLAMNYLDRFLSLEPVKKSRLQLLGATCMFVASKMKETIPLTAEKLCIYTDNSIRPEELLQMELLLVNKLKWNLAAMTPHDFIEHFLSKMPEAEENKQIIRKHAQTFVALCATDVKFISNPPSMVAAGSVVAAVQGLNLRSPNNFLSYYRLTRFLSRVIKCDPDCLRACQEQIEALLESSLRQAQQNMDPKAAEEEEEEEEEVDLACTPTDVRDVDI

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
86
Bovine
86
Dog
86
Xenopus
86
Chicken
86
Zebrafish
71
Horse
0
Sheep
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Regulatory component of the cyclin D1-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also substrate for SMAD3, phosphorylating SMAD3 in a cell-cycle-dependent manner and repressing its transcriptional activity. Component of the ternary complex, cyclin D1/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex. Exhibits transcriptional corepressor activity with INSM1 on the NEUROD1 and INS promoters in a cell cycle-independent manner.

PTMs:

Phosphorylation at Thr-286 by MAP kinases is required for ubiquitination and degradation following DNA damage. It probably plays an essential role for recognition by the FBXO31 component of SCF (SKP1-cullin-F-box) protein ligase complex.

Ubiquitinated, primarily as 'Lys-48'-linked polyubiquitination. Ubiquitinated by a SCF (SKP1-CUL1-F-box protein) ubiquitin-protein ligase complex containing FBXO4 and CRYAB. Following DNA damage it is ubiquitinated by some SCF (SKP1-cullin-F-box) protein ligase complex containing FBXO31. SCF-type ubiquitination is dependent on Thr-286 phosphorylation (By similarity). Ubiquitinated also by UHRF2 apparently in a phosphorylation-independent manner. Ubiquitination leads to its degradation and G1 arrest. Deubiquitinated by USP2; leading to its stabilization.

Subcellular Location:

Nucleus. Cytoplasm. Nucleus membrane.
Note: Cyclin D-CDK4 complexes accumulate at the nuclear membrane and are then translocated to the nucleus through interaction with KIP/CIP family members.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Family&Domains:

Belongs to the cyclin family. Cyclin D subfamily.

Research Fields

· Cellular Processes > Cell growth and death > Cell cycle.   (View pathway)

· Cellular Processes > Cell growth and death > p53 signaling pathway.   (View pathway)

· Cellular Processes > Cell growth and death > Cellular senescence.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Tight junction.   (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > AMPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Wnt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Hedgehog signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Apelin signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Hippo signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Colorectal cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Endometrial cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Glioma.   (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Thyroid cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Bladder cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

· Human Diseases > Cardiovascular diseases > Viral myocarditis.

· Organismal Systems > Endocrine system > Prolactin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Oxytocin signaling pathway.

References

1). Morusin Alleviates Aortic Valve Calcification by Inhibiting Valve Interstitial Cell Senescence Through Ccnd1/Trim25/Nrf2 Axis. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024 (PubMed: 38502885) [IF=15.1]

Application: WB    Species: human    Sample: VICs

Figure 3 Gene expression profiles of VICs under the OM conditioned culturing with or without morusin. A) Volcano map of differentially expressed genes in OM + morusin versus OM (log2M/OM). B) Heatmap for all DEGs in OM + morusin versus OM groups. C) KEGG pathway enrichment of DEGs, bubble colors (deep) indicate the degree of enrichment, bubble size indicates gene counts matched the pathway enrichment, and rich ratio indicates the matched gene counts in the integrated pathway background genes. D) Heatmap for DEGs in cellular senescence pathway. E–H) Immunoblot analysis of CCND1, P53, and P21 expression in VICs from indicated groups (n = 3, each group). Bar plots showing the fold change of CCND1, P53, and P21 expression over control. I) KEGG pathway enrichment of DEGs in the second, fourth, and sixth passages of VICs. J) Heatmap for DEGs in cell cycle pathway. K,L) Immunoblot analysis of CCND1 in the second, fourth, and sixth passages of VICs (n = 3, each group). Bar plots showing the fold change of CCND1 expression over the second passage of VICs. M) RT-PCR analysis of CCND1 mRNA level in the second, fourth, and sixth passages of VICs (n = 3, each group). Bar plots showing the fold change of CCND1 expression over the second passage of VICs. Data are means ± SD. *p < 0.05; **p < 0.01 (ANOVA with Tukey's multiple comparisons test).

Application: IF/ICC    Species: human    Sample: VICs

Figure 1 Cellular senescence is associated with aortic valve calcification. A) GSEA plot showing differential expression of signature genes in the cellular senescence pathway in calcific valve and normal valvular tissue based on the RNA-seq data sets from the GEO database. B) DEG plot showing the differential expression genes between the calcific valve and normal valvular tissue. C) Violin plots representing the expression of P21, P16, and P53 in the aortic valve from CAVD patients, elder and young individuals. D) Representative Vonkossa staining, Alizarin red staining, and immunohistochemical staining of P16, P21, and P53 in aortic valves from CAVD patients and controls. Scale bar 200 µm. E) Immunofluorescent staining of NQO-1 (red), CCND1 (red), and DAPI (blue) in the aortic valve from CAVD patients and controls. Scale bar 100 µm. F) Protein expression of ALP, Runx2, NQO1, and P21 in the aortic valve from CAVD patients (n = 10) and controls (n = 10). Bar plots representing the fold change of specific protein expression over control. Data are means ± SD. **p < 0.01; ***p < 0.001 (unpaired two-tailed Student's t-test).
2). Human umbilical cord mesenchymal stem cells derived extracellular vesicles ameliorate kidney ischemia-reperfusion injury by suppression of senescent tubular epithelial cells - Experimental Study. International journal of surgery (London, England), 2024 (PubMed: 39236098) [IF=12.5]
3). Target deubiquitinase OTUB1 as a therapeatic strategy for BLCA via β-catenin/necroptosis signal pathway. International journal of biological sciences, 2024 (PubMed: 39113709) [IF=8.2]

Application: WB    Species: Mouse    Sample:

Figure 3. OTUB1 facilitates the proliferation and migration of BLCA. A. Relative OTUB1 expression in bladder epithelial immortalized cell SV-HUC and several BLCA cells by western blot and qRT-PCR. B, C. Relative OTUB1 expression following overexpressed or knockdown OTUB1 by western blot. D, F, G. MTT assay, clone formation experiments and healing assay showed the proliferation ability of BLCA cells following overexpressed or knockdown OTUB1. E. Transwell assay showed the invasion ability of BLCA cells following overexpressed or knockdown OTUB1. H, I, J. Cell cycle assay, clone formation experiments and healing assay showed the proliferation ability of BLCA cell after transfecting with shOTUB1 lentivirus. K. Relative cell cycle-related markers expression following overexpressed or knockdown OTUB1 by western blot.
4). GLI1 activation by non-classical pathway integrin αvβ3/ERK1/2 maintains stem cell-like phenotype of multicellular aggregates in gastric cancer peritoneal metastasis. Cell Death & Disease, 2019 (PubMed: 31366904) [IF=8.1]

Application: WB    Species: mouse    Sample: BGC823MCAs and SGC7901MCAs

Fig. S5 |a Western blottingting showing the most pronounced effect of Smo silencing in the shSmo #2 group in BGC823MCAs and SGC7901MCAs. d Western blottingting showing decreased c-Myc and Cyclin D1 in the group of Integrin αvβ3 co-simulator ligand RGD plus ERK1/2 inhibitor PD-184161 or PD-184161 alone compared to the blank control. Each bar in the figure represents the mean ± SEM of triplicates. ns, no significance; *p < 0.05,**p < 0.01.
5). α2,6-Sialylation mediates hepatocellular carcinoma growth in vitro and in vivo by targeting the Wnt/β-catenin pathway. Oncogenesis, 2017 (PubMed: 28553930) [IF=5.9]

Application: WB    Species: human    Sample: Huh-7 cells

Figure 5. Upregulation of ST6Gal-I activates PI3K/Akt, and Wnt/β-catenin signaling pathways in Huh-7 cells. (a, c, e) Main protein components of the PI3K/Akt/MAPK/β-catenin signaling pathway in Huh-7 cells were measured using western blotting.
6). RECQL4 regulates DNA damage response and redox homeostasis in esophageal cancer. Cancer Biology & Medicine, 2021 (PubMed: 33628589) [IF=5.6]

Application: WB    Species: human    Sample: ESCC cells

Figure 4 |The loss of RECQL4 induces cell cycle arrest and cellular senescence. . (D) The protein levels of c-myc, p21, cyclin D, CDK6, cyclin E, Bax, and Bcl-2 were determined by Western blot in stable Tet-on inducible RECQL4 knockdown cell lines (KYSE30 and TE-1 cells) (+Dox) and controls (–Dox). Experiments were independently repeated 3 times. All data indicate the mean ±SD. *P < 0.05; **P < 0.01; ***P < 0.001.

Application: WB    Species: Human    Sample: KYSE30 and TE-1 cells

Figure 4 The loss of RECQL4 induces cell cycle arrest and cellular senescence. (A) Depletion of RECQL4 by siRNA. RECQL4 protein levels were measured by Western blot. KYSE30 and TE-1 cells were transfected with siRNA duplexes (200 nM) specific to RECQL4 or negative oligo in serum-free medium for 4 h, then replaced with complete medium for 24 h. Whole cell extracts were collected for Western blot analysis using RECQL4 antibodies. (B) Cell cycle distributions in RECQL4 knockdown cell lines (KYSE30 and TE-1 cells) and controls were determined by flow cytometry. (C) Cellular senescence was examined by SA-β-gal staining. Microscopic magnification (×200), Scale bar: 50 μm. (D) The protein levels of c-myc, p21, cyclin D, CDK6, cyclin E, Bax, and Bcl-2 were determined by Western blot in stable Tet-on inducible RECQL4 knockdown cell lines (KYSE30 and TE-1 cells) (+Dox) and controls (–Dox). Experiments were independently repeated 3 times. All data indicate the mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001.
7). Inhibition of PRC1 elicits immunogenic cell death by triggering ROS-dependent ER stress in colorectal cancer via the Wnt/β-catenin signaling pathway. Biology direct, 2025 (PubMed: 40847353) [IF=5.5]

Application: WB    Species: human    Sample: CRC cells

Fig. 5 PRC1 activates Wnt/β-catenin signaling pathway in CRC cells. (A) A total of 10,807 targets were selected out by intersecting 21,334 PRC1-related genes screened from cBioPortal, a total of 15,542 differentially expressed genes found out by analyzing two GEO datasets (GSE74602 and GSE24514). (B) A total of 10,807 targets were subject to KEGG analysis to show pathways that PRC1 downstream targets enriched in. (C-F) CRC cells were transfected with si-PRC1 and then treated with 0.5 µM BML-284 (Wnt signaling activator) for 48 h. Western blot was conducted to determine the protein levels of Wnt1, β-catenin, and cyclin D1. (G) The subcellular localization of β-catenin in CRC cells was detected by immunofluorescence assay. *P 
8). A novel long non-coding RNA LINC00355 promotes proliferation of lung adenocarcinoma cells by down-regulating miR-195 and up-regulating the expression of CCNE1. CELLULAR SIGNALLING, 2020 (PubMed: 31689506) [IF=4.4]
9). LncRNA PVT1 promotes the malignant progression of acute myeloid leukaemia via sponging miR-29 family to increase WAVE1 expression. PATHOLOGY, 2021 (PubMed: 33558065) [IF=3.6]

Application: WB    Species: Human    Sample: tumour tissues

Fig. 6 PVT1/WAVE1 axis regulates xenograft growth in vivo. (A) Photograph of the xenograft tumours from different groups. (B) Tumour volumes at the indicated time points and (C) tumour weight are presented. (D) Apoptosis in tumour tissues was evaluated by TUNEL assay. (E) Expression of Ki-67 in tumour tissues was determined by immunohistochemical staining. (F) The protein levels of Bax, Bcl-2, cleaved Caspase 3, p21, and cyclin D1 in tumour tissues was assessed by western blotting. All data are expressed as mean ± standard deviation. *p<0.05, **p<0.01, ***p<0.001 versus the indicated group.
10). ST3Gal IV Mediates the Growth and Proliferation of Cervical Cancer Cells In Vitro and In Vivo Via the Notch/p21/CDKs Pathway. Frontiers in Oncology, 2021 (PubMed: 33598419) [IF=3.5]
Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.